Skip to search formSkip to main contentSkip to account menu

BRL 32872

Known as: BRL-32872 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
IntroductionAtrial dilatation is commonly associated with atrial fibrillation (AF), but the electrophysiological mechanisms and… 
Review
2003
Review
2003
There have been extensive efforts to develop I(Kr) channel blockers as a new antiarrhythmic agent for atrial or ventricular… 
Review
2002
Review
2002
BRL-32872 is a new antiarrhythmic drug with balanced class-III and class-IV actions as categorized by the Vaughan-Williams… 
Highly Cited
2001
Highly Cited
2001
Human ether-a-go-go-related gene (HERG) potassium channels are one primary target for the pharmacological treatment of cardiac… 
1998
1998
The modulation of the protein kinase A-activated chloride current (PKA-I[Cl]) may lead to modification of the cardiac action… 
Highly Cited
1996
Highly Cited
1996
In the search for novel antiarrhythmic agents, compounds with a diversity of electrophysiological actions have been suggested to… 
1995
1995
The effects of N-(3,4-dimethoxyphenyl)-N-[3[[2-(3,4-dimethoxyphenyl) ethyl] propyl]-4-nitrobenzamide hydrochloride (BRL-32872), a… 
1995
1995
The antifibrillatory potential of BRL-32872, a novel antiarrhythmic compound with K+ and Ca2+ channel blocking activities, was…